Myeloproliferative Neoplasms (MPNs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Myeloproliferative
Neoplasms (MPNs) Market Outlook
Thelansis’s “Myeloproliferative
Neoplasms (MPNs) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Palmoplantar
Pustulosis treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Myeloproliferative
Neoplasms (MPNs) Overview
Myeloproliferative
neoplasms (MPNs) are a group of rare, chronic hematologic malignancies
characterized by the clonal expansion of hematopoietic stem cells in the bone
marrow, resulting in overproduction of one or more mature blood cell lines,
including red blood cells, white blood cells, and platelets. The three
“classic” BCR‑ABL1–negative MPNs are polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF). These disorders share
common driver mutations in JAK2, CALR, or MPL,
which lead to constitutive activation of the JAK‑STAT signaling pathway.
Clinically, MPNs are associated with an increased risk of thrombotic and
hemorrhagic complications, as well as splenomegaly and constitutional symptoms.
Over time, they may progress to advanced disease or transform into acute myeloid
leukemia (AML). Management is risk‑stratified and focuses on preventing
vascular events, controlling blood counts, and alleviating symptoms through
phlebotomy, low‑dose aspirin, cytoreductive therapies, JAK inhibitors, and, in
selected cases, allogeneic stem cell transplantation.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment